This review aims at exploring new pharmacogenomics for obesity associated diabetes. The recent advances in pharmacogenomic therapy lead to the gene discovery of various diseases. In this regard we summaries the various genes which are supposed to be involved in occurrence of obesity associated diabetes. Such genes include Interlukin 6, Insulin receptor substrate - 2, Protein Tyrosine Phosphatase 1B, Adiponectin Gene, Islet Amyloid Polypeptide, Ectonucleotide Pyrophosphatase/phosphodiesterase 1 gene, Uncoupling protein, Resistin, Lamins A and C, Leptin Receptor Gene etc. These genes are considered to be responsible for the pathophysiology of obesity associated diabetes and can be used as targeted therapy, paves the way for development of new pharmacogenomic therapy. To list a few, PPAR $\gamma$ agonists, PPAR $\gamma$ and RXR agonists, PPAR $\gamma$ and PPAR$\delta$ agonists, direct modulators of metabolism, PPAR $\alpha$ & PPAR $\gamma$ agonists, canabinoid-1 antagonist, ciliary neurotropic factors and selective $\beta$-3 adrenergic agonists are the pharmacogenomic therapies used in current practice towards the additional advantages. To conclude, pharmacogenomic therapy will provide an added advantage over the currently available conventional therapies and this study will be helpful for future studies towards inventions in pharmacogenomic therapies for obesity associated diabetes.